Submitted:
16 December 2024
Posted:
17 December 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Database of Amyloid Brain PET Images
2.2. Image Scan
2.3. Images and Statistical Analysis
3. Results
4. Discussion
Author Contributions
Funding
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Aschenbrenner AJ, Gordon BA, Benzinger TL, Morris JC, Hassenstab JJ. Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease. Neurology (2018) 91, pp. 859-66. [CrossRef]
- Perani D. FDG-PET and amyloid-PET imaging: the diverging paths. Curr Opin Neurol (2014) 27, pp. 405-13.
- Yoon H, Kim BS, Jeong JH, Kim GH, Park HK, Chun MY, et al. Dual-phase 18F-florbetaben PET provides cerebral perfusion proxy along with beta-amyloid burden in Alzheimer’s disease. NeuroImage: Clinical (2021) 31, 102773. [CrossRef]
- Catafau AM, Bullich S. Amyloid PET imaging: applications beyond Alzheimer’s disease. Clinical and translational imaging (2015) 3, pp. 39-55. [CrossRef]
- Matías-Guiu JA, Oreja-Guevara C, Cabrera-Martín MN, Moreno-Ramos T, Carreras JL, Matías-Guiu J. Amyloid proteins and their role in multiple sclerosis. Considerations in the use of amyloid-PET imaging. Frontiers in neurology (2016) 7, pp. 53. [CrossRef]
- Hatashita S, Wakebe D, Kikuchi Y, Ichijo A. Longitudinal assessment of amyloid-β deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer’s disease. Frontiers in Aging Neuroscience (2019), pp. 251. [CrossRef]
- Li J, Antonecchia E, Camerlenghi M, Chiaravalloti A, Chu Q, Costanzo AD, et al. Correlation of [18F] florbetaben textural features and age of onset of Alzheimer’s disease: a principal components analysis approach. EJNMMI research (2021) 11, pp. 1-14. [CrossRef]
- Jeon S, Kang JM, Seo S, Jeong HJ, Funck T, Lee S, et al. Topographical heterogeneity of Alzheimer’s disease based on MR imaging, tau PET, and amyloid PET. Frontiers in aging neuroscience (2019), 211.
- Tuszynski T, Rullmann M, Luthardt J, Butzke D, Tiepolt S, Gertz H, et al. Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease. European journal of nuclear medicine and molecular imaging (2016) 43, pp. 1077-87. [CrossRef]
- Cho SH, Shin J, Jang H, Park S, Kim HJ, Kim SE, et al. Amyloid involvement in subcortical regions predicts cognitive decline. European journal of nuclear medicine and molecular imaging (2018) 45, pp. 2368-76. [CrossRef]
- Ortner M, Drost R, Heddderich D, Goldhardt O, Müller-Sarnowski F, Diehl-Schmid J, et al. Amyloid PET, FDG-PET or MRI?-the power of different imaging biomarkers to detect progression of early Alzheimer’s disease. BMC neurology (2019) 19, pp. 1-6.
- Schwarz CG, Senjem ML, Gunter JL, Tosakulwong N, Weigand SD, Kemp BJ, et al. Optimizing PiB-PET SUVR change-over-time measurement by a large-scale analysis of longitudinal reliability, plausibility, separability, and correlation with MMSE. Neuroimage (2017) 144, pp. 113-27.
- Morris E, Chalkidou A, Hammers A, Peacock J, Summers J, Keevil S. Diagnostic accuracy of 18F amyloid PET tracers for the diagnosis of Alzheimer’s disease: a systematic review and meta-analysis. European journal of nuclear medicine and molecular imaging (2016) 43, pp. 374-85. [CrossRef]
- Schwarz CG, Gunter JL, Lowe VJ, Weigand S, Vemuri P, Senjem ML, et al. A comparison of partial volume correction techniques for measuring change in serial amyloid PET SUVR. J Alzheimer’s Dis (2019) 67, pp. 181-95. [CrossRef]
- Akamatsu G, Ikari Y, Ohnishi A, Matsumoto K, Nishida H, Yamamoto Y, et al. Voxel-based statistical analysis and quantification of amyloid PET in the Japanese Alzheimer’s disease neuroimaging initiative (J-ADNI) multi-center study. EJNMMI research (2019) 9, pp. 1-9. [CrossRef]
- Shimokawa N, Akamatsu G, Kadosaki M, Sasaki M. Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation. Ann Nucl Med (2020) 34, pp. 629-35. [CrossRef]
- Akamatsu G, Ikari Y, Ohnishi A, Nishida H, Aita K, Sasaki M, et al. Automated PET-only quantification of amyloid deposition with adaptive template and empirically pre-defined ROI. Physics in Medicine & Biology (2016) 61, pp. 5768. [CrossRef]
- Shimokawa N, Akamatsu G, Kadosaki M, Sasaki M. Feasibility study of a PET-only amyloid quantification method: a comparison with visual interpretation. Ann Nucl Med (2020) 34, pp. 629-35. [CrossRef]
- Lundqvist R, Lilja J, Thomas BA, Lötjönen J, Villemagne VL, Rowe CC, et al. Implementation and validation of an adaptive template registration method for 18F-flutemetamol imaging data. Journal of Nuclear Medicine (2013) 54, pp. 1472-8. [CrossRef]
- FreeSurfer https://surfer.nmr.mgh.harvard.edu/ Accessed 1 March 2022.
- PMOD https://www.pmod.com/ Accessed 1 March 2022.
- Chang Y, Li C, Yang H, Wu Y, Xu B, Zhang J, et al. 18F-Florbetaben Amyloid PET Imaging: A Chinese Study in Cognitive Normal Controls, Mild Cognitive Impairment, and Alzheimer’s Disease Patients. Frontiers in Neuroscience (2020), 745.
- Hatashita S, Wakebe D, Kikuchi Y, Ichijo A. Longitudinal assessment of amyloid-β deposition by [18F]-flutemetamol PET imaging compared with [11C]-PIB across the spectrum of Alzheimer’s disease. Frontiers in Aging Neuroscience (2019), 251. [CrossRef]
- Cho SH, Choe YS, Kim YJ, Lee B, Kim HJ, Jang H, et al. Concordance in detecting amyloid positivity between 18F-florbetaben and 18F-flutemetamol amyloid PET using quantitative and qualitative assessments. Scientific Reports (2020) 10, pp. 1-10. [CrossRef]
- Landau SM, Thomas BA, Thurfjell L, Schmidt M, Margolin R, Mintun M, et al. Amyloid PET imaging in Alzheimer’s disease: a comparison of three radiotracers. European journal of nuclear medicine and molecular imaging (2014) 41:1398-407. [CrossRef]
- Schain M, Varnäs K, Cselényi Z, Halldin C, Farde L, Varrone A. Evaluation of two automated methods for PET region of interest analysis. Neuroinformatics (2014) 12, pp. 551-62. [CrossRef]
- Marcoux A, Burgos N, Bertrand A, Teichmann M, Routier A, Wen J, et al. An automated pipeline for the analysis of PET data on the cortical surface. Frontiers in neuroinformatics (2018), 94. [CrossRef]
- Landau SM, Breault C, Joshi AD, Pontecorvo M, Mathis CA, Jagust WJ, et al. Amyloid-β imaging with Pittsburgh compound B and florbetapir: comparing radiotracers and quantification methods. Journal of Nuclear Medicine (2013) 54, pp. 70-7. [CrossRef]
- Chawalparit O, Wontaneeporn N, Muangpaisan W, Thientunyakit T, Charnchaowanish P. MRI hippocampal subfield volume analysis: Comparison between Alzheimer’s disease, mild cognitive impairment, and normal aging subjects in an amyloid PET project. J Alzheimers Dis Parkinsonism (2019) 9, 2161,0460.1000459.
- Ouyang J, Chen KT, Gong E, Pauly J, Zaharchuk G. Ultra-low-dose PET reconstruction using generative adversarial network with feature matching and task-specific perceptual loss. Med Phys (2019) 46, pp. 3555-64. [CrossRef]
- Chen KT, Gong E, de Carvalho Macruz, Fabiola Bezerra, Xu J, Boumis A, Khalighi M, et al. Ultra–low-dose 18F-florbetaben amyloid PET imaging using deep learning with multi-contrast MRI inputs. Radiology (2019) 290, pp. 649-56. [CrossRef]
- Okonkwo DO, Puffer RC, Minhas DS, Beers SR, Edelman KL, Sharpless J, et al. [18F] FDG,[11C] PiB, and [18F] AV-1451 PET imaging of neurodegeneration in two subjects with a history of repetitive trauma and cognitive decline. Frontiers in Neurology (2019), pp. 831. [CrossRef]
- Su Y, D’Angelo GM, Vlassenko AG, Zhou G, Snyder AZ, Marcus DS, et al. Quantitative analysis of PiB-PET with freesurfer ROIs. PloS one (2013) 8, e73377.
- Tsubaki Y, Akamatsu G, Shimokawa N, Katsube S, Takashima A, Sasaki M. Development and evaluation of an automated quantification tool for amyloid PET images. EJNMMI physics (2020) 7, pp. 1-12. [CrossRef]
- Battle MR, Pillay LC, Lowe VJ, Knopman D, Kemp B, Rowe CC, et al. Centiloid scaling for quantification of brain amyloid with [18 F] flutemetamol using multiple processing methods. EJNMMI research (2018) 8, pp. 1-11. [CrossRef]
- Haller S, Montandon M, Lilja J, Rodriguez C, Garibotto V, Herrmann FR, et al. PET amyloid in normal aging: direct comparison of visual and automatic processing methods. Scientific reports (2020) 10, pp. 1-8. [CrossRef]
- Oliveira F, Leuzy A, Castelhano J, Chiotis K, Hasselbalch SG, Rinne J, et al. Data driven diagnostic classification in Alzheimer’s disease based on different reference regions for normalization of PiB-PET images and correlation with CSF concentrations of Aβ species. NeuroImage: Clinical (2018) 20, pp. 603-10.
- Yoon HJ, Cho K, Kim WG, Jeong Y, Jeong J, Kang D. Heterogeneity by global and textural feature analysis in F-18 FP-CIT brain PET images for diagnosis of Parkinson’s disease. Medicine (2021) 100. [CrossRef]
- Son HJ, Jeong YJ, Yoon HJ, Kim JW, Choi G, Park JH, et al. Parkinson disease-related cortical and striatal cognitive patterns in dual time F-18 FP CIT: evidence for neural correlates between the caudate and the frontal lobe. The Quarterly Journal of Nuclear Medicine and Molecular Imaging: Official Publication of the Italian Association of Nuclear Medicine (AIMN)[and] the International Association of Radiopharmacology (IAR),[and] Section of the Society of.. (2017) 63, pp. 379-86.
- Yoon HJ, Jeong YJ, Son HJ, Kang D, Hyun K, Lee M. Optimization of the spatial resolution for the GE discovery PET/CT 710 by using NEMA NU 2-2007 standards. Journal of the Korean Physical Society (2015) 66, pp. 287-94. [CrossRef]
- Jeong YJ, Jeong J, Cheon S, Yoon B, Kim JW, Kang D. Relationship between the washout rate of I-123 MIBG scans and autonomic function in Parkinson’s disease. Plos one (2020) 15, e0229860. [CrossRef]
- MedCalc https://www.medcalc.org/ Accessed 1 June 2022.
- Unal I. Defining an optimal cut-point value in ROC analysis: an alternative approach. Computational and mathematical methods in medicine (2017) 2017.stylefix. [CrossRef]










| Number | Age(mean±SD) | ||||
| Total | M:F* | 70≥:70<** | |||
| FBB | Negative | 12 | 6:6 | 6:6 | 62.42±10.21 |
| Positive | 24 | 12:12 | 12:12 | 67.25±6.63 | |
| FMM | Negative | 40 | 19:21 | 24:16 | 71.78±8.37 |
| Positive | 38 | 20:18 | 22:16 | 71.89±7.52 | |
| FPN | Negative | 33 | 7:16 | 8:15 | 67.57±7.27 |
| Positive | 42 | 14:28 | 30:12 | 73.67±6.67 |
| FC* | Frontal cortex (r/l)* |
| LTC* | Lateral temporal cortex (r/l)* |
| MTC | Mesial temporal cortex (r/l) |
| PC* | Parietal cortex (r/l)* |
| OC* | Occipital cortex (r/l)* |
| GCA* | Anterior cingulate cortex (r/l)* |
| GCP* | Posterior cingulate cortex (r/l)* |
| CN | Caudate nucleus (r/l) |
| PUT | Putamen (r/l) |
| THA | Thalamus (r/l) |
| PQ | precuneus (r/l) |
| CBLCTX** | cerebellum (r/l) |
| Composite | Sum of regions marked with * |
| FBB-FS* | FBB-PMOD | R | |||||||
| Sensitivity | Specificity | Threshold | p-value | Sensitivity | Specificity | Threshold | p-value | ||
| FC | 100.00 | 91.67 | 1.099 | 1.14.E-08 | 91.67 | 100.00 | 1.182 | 2.20.E-08 | 0.96 |
| LTC | 95.83 | 91.67 | 1.140 | 1.22.E-09 | 87.50 | 100.00 | 1.225 | 2.37.E-09 | 0.97 |
| MTC | 75.00 | 100.00 | 1.207 | 9.43.E-05 | 70.83 | 100.00 | 1.218 | 2.43.E-04 | 0.95 |
| PC | 95.83 | 100.00 | 1.210 | 1.07.E-09 | 91.67 | 100.00 | 1.182 | 2.28.E-09 | 0.96 |
| OC | 95.83 | 100.00 | 1.250 | 6.82.E-09 | 91.67 | 100.00 | 1.275 | 3.80.E-08 | 0.97 |
| GCA | 87.50 | 100.00 | 1.237 | 4.95.E-09 | 87.50 | 100.00 | 1.359 | 1.45.E-08 | 0.99 |
| GCP | 95.83 | 100.00 | 1.232 | 3.06.E-09 | 95.83 | 91.67 | 1.341 | 1.52.E-09 | 0.95 |
| CN | 91.67 | 91.67 | 1.174 | 1.70.E-07 | 87.50 | 100.00 | 1.373 | 1.52.E-08 | 0.44 |
| PUT | 95.83 | 83.33 | 1.471 | 1.24.E-07 | 100.00 | 75.00 | 1.466 | 7.76.E-09 | 0.76 |
| THA | 87.50 | 75.00 | 1.371 | 2.92.E-03 | 87.50 | 100.00 | 1.206 | 2.72.E-08 | 0.45 |
| PQ | 100.00 | 91.67 | 1.160 | 1.98.E-09 | 100.00 | 91.67 | 1.173 | 1.39.E-09 | 0.98 |
| Composite | 95.83 | 100.00 | 1.189 | 1.43.E-09 | 91.67 | 100.00 | 1.210 | 3.15.E-09 | 0.97 |
| FMM-FS* | FMM-PMOD | R | |||||||
| Sensitivity | Specificity | Threshold | p-value | Sensitivity | Specificity | Threshold | p-value | ||
| FC | 97.37 | 100.00 | 1.268 | 1.33.E-17 | 100.00 | 95.00 | 1.242 | 5.04.E-17 | 0.98 |
| LTC | 94.74 | 95.00 | 1.264 | 5.33.E-15 | 97.37 | 97.50 | 1.258 | 9.00.E-15 | 0.98 |
| MTC | 26.32 | 92.50 | 1.399 | 3.18.E-01 | 97.37 | 20.00 | 1.093 | 2.38.E-01 | 0.94 |
| PC | 97.37 | 97.50 | 1.283 | 1.37.E-15 | 97.37 | 100.00 | 1.282 | 9.45.E-18 | 0.95 |
| OC | 84.21 | 100.00 | 1.347 | 1.38.E-13 | 84.21 | 97.50 | 1.353 | 2.36.E-12 | 0.96 |
| GCA | 97.37 | 90.00 | 1.323 | 6.68.E-17 | 92.11 | 97.50 | 1.395 | 3.63.E-16 | 0.99 |
| GCP | 100.00 | 95.00 | 1.391 | 4.94.E-19 | 97.37 | 100.00 | 1.598 | 1.30.E-17 | 0.97 |
| CN | 84.21 | 95.00 | 1.27 | 9.15.E-12 | 92.11 | 95.00 | 1.392 | 2.43.E-12 | 0.74 |
| PUT | 89.47 | 82.50 | 1.704 | 8.71.E-12 | 97.37 | 85.00 | 1.256 | 7.65.E-13 | 0.80 |
| THA | 89.47 | 70.00 | 1.725 | 1.36.E-07 | 97.37 | 95.00 | 1.178 | 8.85.E-19 | 0.60 |
| PQ | 94.74 | 100.00 | 1.391 | 2.05.E-18 | 97.37 | 100.00 | 1.332 | 2.51.E-19 | 0.99 |
| Composite | 97.37 | 97.50 | 1.272 | 4.90.E-17 | 97.37 | 100.00 | 1.285 | 5.60.E-17 | 0.98 |
| FPN-FS* | FPN-PMOD | R | |||||||
| Sensitivity | Specificity | Threshold | p-value | Sensitivity | Specificity | Threshold | p-value | ||
| FC | 83.33 | 86.96 | 1.208 | 2.27E-09 | 80.95 | 100.00 | 1.231 | 5.49E-12 | 0.91 |
| LTC | 80.95 | 100.00 | 1.310 | 8.55E-12 | 85.71 | 95.65 | 1.278 | 4.10E-12 | 0.93 |
| MTC | 71.43 | 82.61 | 1.705 | 5.13E-06 | 69.05 | 82.61 | 1.564 | 6.34E-05 | 0.93 |
| PC | 80.95 | 95.65 | 1.286 | 1.08E-11 | 78.57 | 95.65 | 1.218 | 3.64E-12 | 0.94 |
| OC | 73.81 | 100.00 | 1.237 | 2.22E-10 | 90.48 | 86.96 | 1.219 | 2.49E-09 | 0.93 |
| GCA | 64.29 | 100.00 | 1.517 | 3.35E-08 | 71.43 | 100.00 | 1.492 | 2.04E-09 | 0.96 |
| GCP | 83.33 | 86.96 | 1.411 | 1.97E-10 | 73.81 | 100.00 | 1.520 | 3.12E-10 | 0.91 |
| CN | 95.24 | 26.09 | 1.276 | 2.08E-01 | 88.1 | 86.96 | 1.245 | 1.33E-08 | 0.26 |
| PUT | 76.19 | 73.91 | 1.838 | 1.85E-02 | 90.48 | 87.50 | 1.354 | 5.71E-12 | 0.41 |
| THA | 88.10 | 26.09 | 1.558 | 4.30E-01 | 76.19 | 95.65 | 1.164 | 2.44E-10 | 0.25 |
| PQ | 73.81 | 100.00 | 1.371 | 1.60E-11 | 90.48 | 86.96 | 1.229 | 1.37E-12 | 0.96 |
| Composite | 88.10 | 86.96 | 1.237 | 9.41E-12 | 83.33 | 95.65 | 1.234 | 6.70E-13 | 0.95 |
| Comparison of ROC | Composite | FC | LTC | PC | OC | GCA | GCP |
| FPN ~ FBB, PMOD | * | * | * | * | * | * | * |
| FPN ~ FMM, PMOD | * | * | |||||
| FBB ~ FMM, PMOD | * | * | * | * | * | * | * |
| FPN ~ FBB, FS** | * | * | |||||
| FPN ~ FMM, FS** | * | * | * | ||||
| FBB ~ FMM, FS** | * | * | * | * | * | * |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).